ABT-263, a BCL-2 inhibitor, selectively eliminates latently HIV-1-infected cells without viral reactivation.

ABT-263, a BCL-2 inhibitor, selectively eliminates latently HIV-1-infected cells without viral reactivation.

Human immunodeficiency virus-1 (HIV-1) is a hazardous pathogen responsible for causing acquired immunodeficiency syndrome (AIDS). HIV-1 provirus survives in latently infected cells for a long time, despite treatment with combinational anti-retroviral therapy (cART); therefore, it is considered as a...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeong Eun Kang, Hyun Wook Seo, Dong-Eun Kim, Young Hyun Shin, Songmee Bae, Cheol-Hee Yoon
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0322962
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items